+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Graft Versus Host Disease Treatment Market - Global Forecast 2026-2032- Product Image
Graft Versus Host Disease Treatment Market - Global Forecast 2026-2032- Product Image
New

Graft Versus Host Disease Treatment Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 192 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5532915
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

As the graft versus host disease treatment market becomes more complex, senior leaders in healthcare must leverage market intelligence to navigate clinical development, regulatory frameworks, and evolving commercial opportunities. This report distills comprehensive insights to help decision-makers optimize strategic direction and maximize therapeutic and business impact within this competitive landscape.

Market Snapshot: Graft Versus Host Disease Treatment Market Size & Trajectory

The graft versus host disease treatment market advanced from USD 2.28 billion in 2025 to USD 2.50 billion in 2026, and is on track to reach USD 4.70 billion by 2032—driven by a robust compound annual growth rate (CAGR) of 10.83%. This notable upward trend underscores continued investment, heightened innovation, and a persistent need for effective GVHD therapies globally.

Scope & Segmentation

This analysis breaks down the core structure of the graft versus host disease treatment market, providing actionable perspectives for focused strategy and market positioning:

  • Treatment Class: Covers Calcineurin Inhibitors, Corticosteroids, JAK Inhibitors, and Monoclonal Antibodies, reflecting the spectrum from established to emerging immunomodulatory agents.
  • Route of Administration: Includes Intravenous, Oral, and Subcutaneous delivery, each shaping patient experience and influencing healthcare resource allocation.
  • End User: Considers Ambulatory Care Centers, Hospitals, and Specialty Clinics, offering insights into points of patient management within diverse care ecosystems.
  • Distribution Channel: Focuses on Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy pathways, guiding supply chain and commercialization approaches.
  • Geographic Regions: Analyzes trends across Americas, Europe, Middle East & Africa, and Asia-Pacific, capturing regional market drivers and access challenges.
  • Technology & Innovation: Encompasses targeted immunomodulators, combination regimens, biomarker-guided therapeutic selection, and digital health integration to support precision medicine.
  • Regulatory Pathways: Highlights accelerated approvals, adaptive clinical trial designs, and region-specific reimbursement strategies influencing time-to-market and patient access.

Key Takeaways for Senior Stakeholders

  • Innovative targeted therapies are steadily replacing nonspecific immunosuppression, capitalizing on advances in T cell biology to improve patient outcomes.
  • Regulatory environments are adapting, with new mechanisms expediting access to steroid-refractory therapies and enabling adaptive clinical study designs for iterative progress.
  • Value-based reimbursement and real-world evidence are now critical for market adoption, requiring sponsors to demonstrate not just efficacy, but patient impact in diverse population settings.
  • Expansion of oral and subcutaneous formulations is facilitating the shift toward outpatient care pathways, enhancing flexibility for providers and patients.
  • Regional supply and manufacturing strategies—especially in Asia-Pacific—not only address access needs but also differentiate market positioning amid shifting global dynamics.
  • Integration of digital platforms and real-world data augments evidence portfolios, supporting more patient-centric care delivery models and continuous product optimization.

Tariff Impact & Supply Chain Considerations

Recent trade policy changes and related tariff adjustments have prompted organizations to reassess procurement and logistics strategies for GVHD treatments. Fluctuating tariffs on biologic raw materials and active pharmaceutical ingredients are heightening manufacturing costs, motivating manufacturers to diversify supplier relationships, implement regionalized fill-finish operations, and reinforce contractual agreements to minimize risk exposure throughout global supply chains. The inherent complexity of cold-chain logistics for these therapies is further compounded by tariff-driven cost pressures, accelerating investments in supply chain redundancy and comprehensive contingency planning. These policy fluctuations also shape the timing and sequencing of product launches and influence contract negotiations with payers, reinforcing the industry’s need for operational resilience and agility across the entire value chain.

Methodology & Data Sources

This report utilizes a transparent, evidence-based methodology, incorporating structured interviews with clinical and regulatory stakeholders, systematic reviews of published literature, examination of regulatory filings and public trial data, and scenario analysis for supply chain and tariff effects. Each insight is validated through triangulation, ensuring alignment with senior executive needs.

Why This Report Matters

  • Empowers C-suite executives and strategic planners to benchmark contemporary clinical and commercial models within the GVHD therapeutic space, identifying innovation and risk factors.
  • Provides actionable clarity for R&D prioritization, market entry strategies, and stakeholder engagement efforts by outlining distinct opportunities across treatment segments and geographic regions.
  • Aligns data generation, operational plans, and regulatory navigation with evolving payer and market access imperatives for sustained organizational resilience.

Conclusion

The graft versus host disease treatment market is characterized by layered complexity alongside opportunity. Through an integrated, data-driven approach, this analysis equips senior leaders to strengthen their market presence, optimize patient access, and deliver improved clinical and business outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Graft Versus Host Disease Treatment Market, by Treatment Class
8.1. Calcineurin Inhibitors
8.2. Corticosteroids
8.3. JAK Inhibitors
8.4. Monoclonal Antibodies
9. Graft Versus Host Disease Treatment Market, by Route Of Administration
9.1. Intravenous
9.2. Oral
9.3. Subcutaneous
10. Graft Versus Host Disease Treatment Market, by End User
10.1. Ambulatory Care Centers
10.2. Hospitals
10.3. Specialty Clinics
11. Graft Versus Host Disease Treatment Market, by Distribution Channel
11.1. Hospital Pharmacy
11.2. Online Pharmacy
11.3. Retail Pharmacy
12. Graft Versus Host Disease Treatment Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Graft Versus Host Disease Treatment Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Graft Versus Host Disease Treatment Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Graft Versus Host Disease Treatment Market
16. China Graft Versus Host Disease Treatment Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. AbbVie Inc.
17.6. Amgen Inc.
17.7. Astellas Pharma Inc.
17.8. Bristol Myers Squibb Company
17.9. ElsaLyn Biopharma Inc.
17.10. Equillium, Inc.
17.11. Incyte Corporation
17.12. Janssen Pharmaceuticals, Inc.
17.13. Kadmon Corporation, LLC
17.14. Mallinckrodt plc
17.15. Mesoblast Limited
17.16. Novartis AG
17.17. Omeros Corporation
17.18. Pfizer Inc.
17.19. Sanofi S.A.
17.20. Sobi AB
17.21. Takeda Pharmaceutical Company Limited
List of Figures
FIGURE 1. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY CALCINEURIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY CALCINEURIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 47. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 48. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 49. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 50. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 51. NORTH AMERICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. NORTH AMERICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 53. NORTH AMERICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 54. NORTH AMERICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 55. NORTH AMERICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 56. LATIN AMERICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. LATIN AMERICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 58. LATIN AMERICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 59. LATIN AMERICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 60. LATIN AMERICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 61. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 62. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 63. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 64. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 65. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 66. EUROPE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. EUROPE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 68. EUROPE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 69. EUROPE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 70. EUROPE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 71. MIDDLE EAST GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. MIDDLE EAST GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 73. MIDDLE EAST GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 74. MIDDLE EAST GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 75. MIDDLE EAST GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 76. AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 78. AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 79. AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 80. AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 81. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 83. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 84. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 85. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. ASEAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. ASEAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 89. ASEAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 90. ASEAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 91. ASEAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 92. GCC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GCC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 94. GCC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 95. GCC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 96. GCC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 97. EUROPEAN UNION GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. EUROPEAN UNION GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 99. EUROPEAN UNION GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 100. EUROPEAN UNION GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 101. EUROPEAN UNION GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 102. BRICS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. BRICS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 104. BRICS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 105. BRICS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 106. BRICS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 107. G7 GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. G7 GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 109. G7 GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 110. G7 GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 111. G7 GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 112. NATO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 113. NATO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 114. NATO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 115. NATO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 116. NATO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 119. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 120. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 121. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 122. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 123. CHINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 124. CHINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 125. CHINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 126. CHINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 127. CHINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Graft Versus Host Disease Treatment market report include:
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Bristol Myers Squibb Company
  • ElsaLyn Biopharma Inc.
  • Equillium, Inc.
  • Incyte Corporation
  • Janssen Pharmaceuticals, Inc.
  • Kadmon Corporation, LLC
  • Mallinckrodt plc
  • Mesoblast Limited
  • Novartis AG
  • Omeros Corporation
  • Pfizer Inc.
  • Sanofi S.A.
  • Sobi AB
  • Takeda Pharmaceutical Company Limited

Table Information

Report AttributeDetails
No. of Pages192
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.5 Billion
Forecasted Market Value ( USD ) by 2032 $ 4.7 Billion
Compound Annual Growth Rate10.8%
Regions CoveredGlobal
No. of Companies Mentioned18

Related Topics

Related Reports

Graft Versus Host Disease (GvHD) - Pipeline Insight, 2025 - Product Image

Graft Versus Host Disease (GvHD) - Pipeline Insight, 2025

  • Drug Pipelines
  • 180 Pages
  • Global
From
Graft Versus Host Disease (GVHD) Treatment Market Report 2025 - Product Image

Graft Versus Host Disease (GVHD) Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Graft Versus Host Disease Market - A Global and Regional Analysis: Focus on Country and Region, 2025-2035 - Product Image

Graft Versus Host Disease Market - A Global and Regional Analysis: Focus on Country and Region, 2025-2035

  • Report
  • Global
From
Graft Versus Host Disease (GvHD) Treatment - Global Strategic Business Report - Product Image

Graft Versus Host Disease (GvHD) Treatment - Global Strategic Business Report

  • Report
  • 296 Pages
  • Global
From
Graft Versus Host Disease (GVHD) Epidemiology Forecast 2025-2034 - Product Image

Graft Versus Host Disease (GVHD) Epidemiology Forecast 2025-2034

  • Report
  • 150 Pages
  • Global
From

About the Graft Versus Host Disease Drug Market

Graft Versus Host Disease (GVHD) is a type of immune disorder that occurs when transplanted donor cells attack the recipient's body. It is a common complication of bone marrow and stem cell transplants. Treatment for GVHD typically involves immunosuppressive drugs, such as corticosteroids, calcineurin inhibitors, and monoclonal antibodies. These drugs are used to reduce inflammation and suppress the immune system, allowing the body to accept the donor cells. The GVHD drug market is a rapidly growing segment of the immune disorder drug market. It is driven by the increasing prevalence of GVHD, as well as the development of new drugs and treatments. The market is expected to continue to grow in the coming years, as more treatments become available and the demand for GVHD drugs increases. Some of the major companies in the GVHD drug market include Novartis, Celgene, Gilead Sciences, and Bristol-Myers Squibb. These companies are involved in the development and marketing of GVHD drugs, as well as other immune disorder drugs. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.